Artificial intelligence is leveling up the fight against infectious diseases

In a new review, Presidential Assistant Professor Cesar de la Fuente and co-authors assess the progress, limitations, and promise of research in AI and infectious diseases.

Artificial intelligence is a new addition to the infectious disease researcher’s toolbox. Yet in merely half a decade, AI has accelerated progress on some of the most urgent issues in medical science and public health. Researchers in this field blend knowledge of life sciences with skill in computation, chemistry and design, satisfying decades-long appeals for interdisciplinary tactics to treat these disorders and stop their spread.

Cesar de la Fuente at the BioPond in James Kaskey Memorial Park
César de la Fuente, Presidential Assistant Professor with appointments in the School of Engineering and Applied Science and Perelman School of Medicine. (Image: Eric Sucar)

Diseases are “infectious” when they are caused by organisms, including parasites, viruses, bacteria, and fungi. People and animals can contract infectious diseases from their environments or food, or through interactions with one another. Some, but not all, are contagious.

Infectious diseases are an intractable global challenge, posing problems that continue to grow in severity even as science has offered a steady pace of solutions. Diseases that were once treatable by drugs have become resistant, and new drug discovery is more costly than ever. Uneven resource distribution means that certain parts of the world are perennial hotspots for diseases that others never fear.

Cesar de la Fuente brings an expert eye to how AI has transformed infectious disease research in a review published in Science with co-authors Felix Wong and James J. Collins from MIT.

De la Fuente is a Presidential Assistant Professor in the Department of Bioengineering and the Department of Chemical and Biomolecular Engineering at the School of Engineering and Applied Science, with additional primary appointments in psychiatry and microbiology in the Perelman School of Medicine.

De la Fuente and co-authors assess the progress, limitations, and promise of research in AI and infectious diseases in three major areas of inquiry: anti-infective drug discovery, infection biology, and diagnostics for infectious diseases. In the review, the researchers discuss approaches for detecting, treating, and understanding infectious diseases, underscoring the progress supported by AI in each case. “We suggest future applications of AI,” they write, “and how it might be harnessed to help control infectious disease outbreaks and pandemics.”

Read more at Penn Engineering Today.